© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease
From the Department of Medicine (X.J., F.P., M.L., L.B., A.R.T.), Columbia University, New York, NY; Bassett Health Care (T.A.P., R.G.R.), Cooperstown, NY; and Harlem Hospital (C.K.F.), New York, NY.
Correspondence to Dr Xian-cheng Jiang, Division of Molecular Medicine, Department of Medicine, Room P&S 8-401, Columbia University, 630 West 168th St, New York, NY 10032. E-mail xcj1{at}columbia.edu
Abstract—Only a fraction of the clinical complications of atherosclerosis are explained by known risk factors. Animal studies have shown that plasma sphingomyelin (SM) levels are closely related to the development of atherosclerosis. SM carried into the arterial wall on atherogenic lipoproteins may be locally hydrolyzed by sphingomyelinase, promoting lipoprotein aggregation and macrophage foam cell formation. A novel, high-throughput, enzymatic method to measure plasma SM levels has been developed. Plasma SM levels were related to the presence of coronary artery disease (CAD) in a biethnic angiographic case-control study (279 cases and 277 controls). Plasma SM levels were higher in CAD patients than in control subjects (60±29 versus 49±21 mg/dL, respectively; P<0.0001). Moreover, the ratio of SM to SM+phosphatidylcholine (PC) was also significantly higher in cases than in controls (0.33±0.13 versus 0.29±0.10, respectively; P<0.0001). Similar relationships were observed in African Americans and whites. Plasma SM levels showed a significant correlation with remnant cholesterol levels (r=0.51, P<0.0001). By use of multivariate logistic regression analysis, plasma SM levels and the SM/(SM+PC) ratio were found to have independent predictive value for CAD after adjusting for other risk factors, including remnants. The odds ratio (OR) for CAD was significantly higher for the third and fourth quartiles of plasma SM levels (OR 2.81 [95% CI 1.66 to 4.80] and OR 2.33 [95% CI 1.38 to 3.92], respectively) as well as the SM/(SM+PC) ratio (OR 1.95 [95% CI 1.10 to 3.45] and OR 2.33 [95% CI 1.34 to 4.05], respectively). The findings indicate that human plasma SM levels are positively and independently related to CAD. Plasma SM levels could be a marker for atherogenic remnant lipoprotein accumulation and may predict lipoprotein susceptibility to arterial wall sphingomyelinase.
Key Words: sphingomyelin • risk factors • coronary artery disease
This article has been cited by other articles:
 |
|
 |
|
  C. M. Devlin, A. R. Leventhal, G. Kuriakose, E. H. Schuchman, K. J. Williams, and I. Tabas Acid Sphingomyelinase Promotes Lipoprotein Retention Within Early Atheromata and Accelerates Lesion Progression Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1723 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Shah, G. Yang, I. Lee, J. Bielawski, Y. A. Hannun, and F. Samad Protection from High Fat Diet-induced Increase in Ceramide in Mice Lacking Plasminogen Activator Inhibitor 1 J. Biol. Chem., May 16, 2008; 283(20): 13538 - 13548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Glaros, W. S. Kim, C. M. Quinn, W. Jessup, K.-A. Rye, and B. Garner Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice J. Lipid Res., February 1, 2008; 49(2): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tabas, K. J. Williams, and J. Boren Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications Circulation, October 16, 2007; 116(16): 1832 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Samad, K. D. Hester, G. Yang, Y. A. Hannun, and J. Bielawski Altered Adipose and Plasma Sphingolipid Metabolism in Obesity: A Potential Mechanism for Cardiovascular and Metabolic Risk Diabetes, September 1, 2006; 55(9): 2579 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dong, J. Liu, B. Lou, Z. Li, X. Ye, M. Wu, and X.-C. Jiang Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice J. Lipid Res., June 1, 2006; 47(6): 1307 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Nelson, X.-C. Jiang, I. Tabas, A. Tall, and S. Shea Plasma Sphingomyelin and Subclinical Atherosclerosis: Findings from the Multi-Ethnic Study of Atherosclerosis Am. J. Epidemiol., May 15, 2006; 163(10): 903 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rubin, H. J. Kim, T. A. Pearson, S. Holleran, R. Ramakrishnan, and L. Berglund Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a] J. Lipid Res., May 1, 2006; 47(5): 982 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. Lee, A. Lesimple, M. Denis, J. Vincent, A. Larsen, O. Mamer, L. Krimbou, J. Genest, and M. Marcil Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B J. Lipid Res., March 1, 2006; 47(3): 622 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Hojjati and X.-C. Jiang Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine J. Lipid Res., March 1, 2006; 47(3): 673 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nilsson and R.-D. Duan Absorption and lipoprotein transport of sphingomyelin J. Lipid Res., January 1, 2006; 47(1): 154 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. Subbaiah, L. R. Gesquiere, and K. Wang Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin J. Lipid Res., December 1, 2005; 46(12): 2699 - 2705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Williams and I. Tabas Lipoprotein Retention--and Clues for Atheroma Regression Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1536 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Williams, M.-L. Liu, Y. Zhu, X. Xu, W. R. Davidson, P. McCue, and K. Sharma Loss of Heparan N-Sulfotransferase in Diabetic Liver: Role of Angiotensin II Diabetes, April 1, 2005; 54(4): 1116 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Hojjati, Z. Li, H. Zhou, S. Tang, C. Huan, E. Ooi, S. Lu, and X.-C. Jiang Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice J. Biol. Chem., March 18, 2005; 280(11): 10284 - 10289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schlitt, M. R. Hojjati, H. von Gizycki, K. J. Lackner, S. Blankenberg, B. Schwaab, J. Meyer, H. J. Rupprecht, and X.-C. Jiang Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles J. Lipid Res., February 1, 2005; 46(2): 196 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tabas Sphingolipids and Atherosclerosis: A Mechanistic Connection? A Therapeutic Opportunity? Circulation, November 30, 2004; 110(22): 3400 - 3401. [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Park, R. L. Panek, S. B. Mueller, J. C. Hanselman, W. S. Rosebury, A. W. Robertson, E. K. Kindt, R. Homan, S. K. Karathanasis, and M. D. Rekhter Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E-Knockout Mice Circulation, November 30, 2004; 110(22): 3465 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-y. Morita, M. Kawabe, A. Sakurai, K. Okuhira, A. Vertut-Doi, M. Nakano, and T. Handa Ceramide in Lipid Particles Enhances Heparan Sulfate Proteoglycan and Low Density Lipoprotein Receptor-related Protein-mediated Uptake by Macrophages J. Biol. Chem., June 4, 2004; 279(23): 24355 - 24361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Webb, M. C. de Beer, F. C. de Beer, and D. R. van der Westhuyzen ApoB-containing lipoproteins in apoE-deficient mice are not metabolized by the class B scavenger receptor BI J. Lipid Res., February 1, 2004; 45(2): 272 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Noh and S. I. Koo Egg Sphingomyelin Lowers the Lymphatic Absorption of Cholesterol and {alpha}-Tocopherol in Rats J. Nutr., November 1, 2003; 133(11): 3571 - 3576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Leventhal, W. Chen, A. R. Tall, and I. Tabas Acid Sphingomyelinase-deficient Macrophages Have Defective Cholesterol Trafficking and Efflux J. Biol. Chem., November 21, 2001; 276(48): 44976 - 44983. [Abstract] [Full Text] [PDF]
|
|